相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate
Gregory D. Huhn et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications?
C. Schwarze-Zander et al.
HIV MEDICINE (2020)
The Magic of Randomization versus the Myth of Real-World Evidence
Rory Collins et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV
Aoife Lacey et al.
AIDS (2020)
Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials
Xingbao Tao et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study
Bernard Surial et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort
J. M. Llibre et al.
HIV MEDICINE (2019)
Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back
Ana Milinkovic et al.
AIDS (2019)
Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naive and -experienced patients
Thomas Theo Brehm et al.
MEDICINE (2019)
Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting
Kai Juhani Kauppinen et al.
AIDS PATIENT CARE AND STDS (2019)
Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort
Lise Cuzin et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service
Dane Turner et al.
AIDS RESEARCH AND THERAPY (2019)
Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment
Edwin DeJesus et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2018)
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2018 Recommendations of the International Antiviral Society-USA Panel
Michael S. Saag et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naive human immunodeficiency virus-infected patients compared to non-nucleoside and protease inhibitor-based regimens in a real-world clinical setting A retrospective cohort study
Karen Jacobson et al.
MEDICINE (2018)
Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients
C. Hoffmann et al.
HIV MEDICINE (2017)
Similar efficacy and tolerability of raltegravir-based antiretroviral therapy in HIV-infected patients, irrespective of age group, burden of comorbidities and concomitant medication: Real-life analysis of the German 'WIP' cohort
U. Naumann et al.
INTERNATIONAL JOURNAL OF STD & AIDS (2017)
Tolerability of integrase inhibitors in a real-life setting
Judit Penafiel et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Paul E. Sax et al.
LANCET (2017)
Neuropsychiatric adverse effects on dolutegravir: an emerging concern in Europe
Amelie Menard et al.
AIDS (2017)
Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice
Mark G. J. de Boer et al.
AIDS (2016)
Efficacy of raltegravir-containing regimens in antiretroviral-naive and -experienced individuals in routine clinical practice
M. Jaeckle et al.
INTERNATIONAL JOURNAL OF STD & AIDS (2016)
Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis
Steve Kanters et al.
LANCET HIV (2016)
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF in HIV-Infected Patients With Mild-to-Moderate Renal Impairment
Frank A. Post et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2015)
Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1
Jeffrey L. Lennox et al.
ANNALS OF INTERNAL MEDICINE (2014)
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
Bonaventura Clotet et al.
LANCET (2014)
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial
Jose R. Arribas et al.
LANCET INFECTIOUS DISEASES (2014)
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial
Anton Pozniak et al.
LANCET INFECTIOUS DISEASES (2014)
Efficacy of Initial Antiretroviral Therapy for HIV-1 Infection in Adults: A Systematic Review and Meta-Analysis of 114 Studies with up to 144 Weeks' Follow-Up
Frederick J. Lee et al.
PLOS ONE (2014)
Safety, Tolerability, and Efficacy of Raltegravir in a Diverse Cohort of HIV-Infected Patients: 48-Week Results from the REALMRK Study
Kathleen E. Squires et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2013)
Dolutegravir plus Abacavir-Lamivudine for the Treatment of HIV-1 Infection
Sharon L. Walmsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
Paul E. Sax et al.
LANCET (2012)
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
Edwin DeJesus et al.
LANCET (2012)
A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV plus homeless and marginally housed people
David R. Bangsberg et al.
AIDS (2010)
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
Jeffrey L. Lennox et al.
LANCET (2009)
分享论文
